We analyzed the efficacy of eight clinically relevant c-MET targeting agents for their radiosensitizing and CSC eliminating potential to assess the hypothesis that c-MET-dependency represents a therapeutically exploitable vulnerability in HNSCC cells. The gene discussed is MET; the disease is head and neck squamous cell carcinoma.